News: ADMD Appoints Dr. Darrell R. Fisher to its Medical Advisory Board
KENNEWICK, Wash., June 5, 2014 -- Advanced Medical Isotope Corporation ("AMIC") (OTCBB: ADMD), a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications, today announced that Dr. Darrell R. Fisher has been appointed to the AMIC Medical Advisory Board, joining Chairman Dr. Barry D. Pressman.
Dr. Fisher is known internationally for his expertise in the dosimetry and consequences of exposure to radioactive materials, including medically administered radiopharmaceuticals for diagnostic and therapeutic benefit. Dr. Fisher is president of the Health Physics Society, an international organization of professionals engaged in the science and practice of radiation safety. He is a principal nuclear medicine dosimetrist with the Dade Moeller Health Group, Richland, Washington, a leading medical physics services provider. Dr. Fisher is a Fellow of the Health Physics Society and a recipient of its prestigious Elda Anderson Award. He also serves on the Medical Internal Radiation Dose Committee of the Society of Nuclear Medicine and Molecular Imaging, which develops standard methods for radiopharmaceutical dosimetry.
Dr. Fisher previously served on the U.S. Nuclear Regulatory Commission's Advisory Committee on the Medical Uses of Isotopes. He recently completed a 35-year career at the Pacific Northwest National Laboratory (PNNL), where he led the Isotope Sciences Program. He holds six patents, including patents licensed by AMIC for its brachytherapy products.
AMIC CEO, Chairman and Founder James C. Katzaroff remarked: "I am delighted that after many years of working together on our yttrium-90 brachytherapy product line, Dr. Fisher has joined our Medical Advisory Board. I believe that Dr. Fisher's expertise in dosimetry and the health effects of radiation as well as his extensive technical knowledge of our yttrium-90 brachytherapy products,